Why the study?
Heart failure patients are at high risk of polypharmacy and potentially inappropriate prescribing leading to poor clinical outcomes.
How can potentially inappropriate prescribing be avoided and guideline-directed medical therapies optimized in patients with HFrEF?
How can potentially inappropriate prescribing be avoided and guideline-directed medical therapies optimized in patients with HFrEF?
This ESC position statement provides a comprehensive prescribing review tool to mitigate polypharmacy risks and optimize guideline-directed medical therapy in patients with HFrEF.
Provides clinicians a tool to reduce polypharmacy and optimize GDMT in HFrEF; extends ESC guidance into an actionable prescribing review.
Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts' opinions.
No takes yet. Share an insight, caveat, or question.
Hadidi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: